Editas Medicine, Inc.
EDIT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $32,314 | $78,123 | $19,712 | $25,544 |
| % Growth | -58.6% | 296.3% | -22.8% | – |
| Cost of Goods Sold | $0 | $6,064 | $6,337 | $5,053 |
| Gross Profit | $32,314 | $72,059 | $13,375 | $20,491 |
| % Margin | 100% | 92.2% | 67.9% | 80.2% |
| R&D Expenses | $199,247 | $177,651 | $174,958 | $142,507 |
| G&A Expenses | $71,987 | $69,653 | $70,704 | $76,183 |
| SG&A Expenses | $71,987 | $69,653 | $70,704 | $76,183 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $12,232 | -$6,064 | -$6,337 | -$5,053 |
| Operating Expenses | $283,466 | $241,240 | $239,325 | $213,637 |
| Operating Income | -$251,152 | -$169,181 | -$225,950 | -$193,146 |
| % Margin | -777.2% | -216.6% | -1,146.3% | -756.1% |
| Other Income/Exp. Net | $14,059 | $15,962 | $5,518 | $644 |
| Pre-Tax Income | -$237,093 | -$153,219 | -$220,432 | -$192,502 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$237,093 | -$153,219 | -$220,432 | -$192,502 |
| % Margin | -733.7% | -196.1% | -1,118.3% | -753.6% |
| EPS | -2.88 | -2.02 | -3.21 | -2.85 |
| % Growth | -42.6% | 37.1% | -12.6% | – |
| EPS Diluted | -2.88 | -2.02 | -3.21 | -2.85 |
| Weighted Avg Shares Out | 82,338 | 75,966 | 68,665 | 67,619 |
| Weighted Avg Shares Out Dil | 82,338 | 75,966 | 68,665 | 67,619 |
| Supplemental Information | – | – | – | – |
| Interest Income | $14,062 | $17,566 | $5,518 | $607 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $5,809 | $6,064 | $6,337 | $5,053 |
| EBITDA | -$233,111 | -$163,117 | -$219,613 | -$188,093 |
| % Margin | -721.4% | -208.8% | -1,114.1% | -736.3% |